Eagle Bay Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Eagle Bay Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-65	Closed	-$29.5K	–	262
2025 Q4	$29.5K	Buy	+65	New	+$28K	0.02%	209
2025 Q1	–	Sell	-54	Closed	-$21.7K	–	928
2024 Q4	$21.7K	Hold	54	–	–	0.01%	449
2024 Q3	$25.1K	Hold	54	–	–	0.01%	583
2024 Q2	$25.3K	Hold	54	–	–	0.02%	414
2024 Q1	$22.6K	Buy	54 +23	+74%	+$9.72K	0.01%	409
2023 Q4	$12.6K	Hold	31	–	–	0.01%	483
2023 Q3	$10.8K	Hold	31	–	–	0.01%	590
2023 Q2	$10.9K	Hold	31	–	–	0.01%	593
2023 Q1	$9.77K	Hold	31	–	–	0.01%	596
2022 Q4	$8.95K	Hold	31	–	–	0.01%	617
2022 Q3	$9K	Hold	31	–	–	0.01%	615
2022 Q2	$8.73K	Buy	+31	New	+$8.3K	0.01%	661
2022 Q1	–	Sell	-1	Closed	-$1K	–	963
2021 Q4	$1K	Sell	1 -51	-98%	-$9.92K	﹤0.01%	1064
2021 Q3	$9K	Hold	52	–	–	0.01%	755
2021 Q2	$12K	Buy	+52	New	+$10.9K	0.01%	655

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Eagle Bay Advisors's VRTX Position: Q1 2026 in Review

Eagle Bay Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 65 shares — an estimated $29.5K sold.

Eagle Bay Advisors first reported a position in VRTX in Q2 2021 and held it in 15 quarters. The position peaked at $29.5K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Eagle Bay Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Eagle Bay Advisors sold 65 Vertex Pharmaceuticals shares in Q1 2026, an estimated $29.5K.
Eagle Bay Advisors first reported a position in Vertex Pharmaceuticals in Q2 2021 and held it in 15 quarters.
Eagle Bay Advisors's Vertex Pharmaceuticals position peaked at $29.5K in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Eagle Bay Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.